Drug Trial Radar · NCT06952699
A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)
Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
88
Planned (sponsor's estimate)
Start
May 6, 2025
Primary completion
Nov 30, 2026
Study completion Nov 30, 2026
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- May 1, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Narcolepsy without cataplexy or Narcolepsy Type 2 (NT2) is a lifelong condition that makes people very sleepy during the day, regardless of how much sleep they get at night. People with NT2 may fall asleep suddenly, have trouble staying awake during the day, or may not be able to sleep well at night. They may have difficulty thinking clearly, paying attention, or remembering things, during the day. These symptoms can make daily activities like driving, working, or caring for their families challenging, impacting their quality of life. Orexin is a chemical made in the brain that helps keep a person awake and alert. TAK-360 acts like orexin. Previous studies have shown that medicines that act like orexin may keep people awake. The main aim of this study is to learn how safe TAK-360 is and how well adults with NT2 tolerate it. Researchers also want to find out if TAK-360 can help people with NT2 stay awake and determine the right dosage needed to do that. Participants will be randomly (by chance, like drawing names from a hat) assigned to get either TAK-360 or placebo in the treatment period. The placebo is a pill that looks just like TAK-360 but does not have any medicine in it. Using a placebo helps researchers learn about the real effect of the treatment.
Conditions
- Narcolepsy Type 2
Interventions
TAK-360Drug
TAK-360 tablet.
PlaceboOther
TAK-360 matching placebo tablet.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With at Least One Treatment-emergent Adverse Event (TEAE)Time frame: Up to 15 Weeks
Locations
52 sites in 7 countries. Site status is shown where the registry gives one.
Takeda Site 36
Auburn, Alabama · Active not recruiting
Takeda Site 39
Chandler, Arizona · Withdrawn
Takeda Site 40
Chula Vista, California · Recruiting
Takeda Site 14
Redwood City, California · Recruiting
Takeda Site 10
Santa Ana, California · Recruiting
Takeda Site 1
Colorado Springs, Colorado · Recruiting
Takeda Site 48
Bradenton, Florida · Recruiting
Takeda Site 13
Brandon, Florida · Recruiting
Takeda Site 46
Jacksonville, Florida · Recruiting
Takeda Site 44
Miami, Florida · Recruiting
Takeda Site 35
Miami, Florida · Recruiting
Takeda Site 3
Orlando, Florida · Recruiting
Takeda Site 33
Orlando, Florida · Active not recruiting
Takeda Site 32
Atlanta, Georgia · Recruiting
Takeda Site 49
Bowie, Maryland · Recruiting
Takeda Site 50
Lansing, Michigan · Recruiting
Takeda Site 34
Lathrup Village, Michigan · Recruiting
Takeda Site 4
St Louis, Missouri · Recruiting
Takeda Site 37
Middletown, New Jersey · Recruiting
Takeda Site 8
Denver, North Carolina · Recruiting
Takeda Site 6
Huntersville, North Carolina · Recruiting
Takeda Site 41
Winston-Salem, North Carolina · Recruiting
Takeda Site 5
Cincinnati, Ohio · Recruiting
Takeda Site 45
Cleveland, Ohio · Recruiting
Takeda Site 2
Columbia, South Carolina · Recruiting
Takeda Site 38
Austin, Texas · Recruiting
Takeda Site 43
Dallas, Texas · Withdrawn
Takeda Site 42
El Paso, Texas · Completed
Takeda Site 47
Mansfield, Texas · Withdrawn
Takeda Site 7
San Antonio, Texas · Recruiting
Takeda Site 11
Norfolk, Virginia · Recruiting
Takeda Site 28
Beijing, Beijing Municipality, China · Recruiting
Takeda Site 29
Guangzhou, Guangzhou, China · Recruiting
Takeda Site 51
Changchun, Jilin, China · Recruiting
Takeda Site 27
Shanghai, Shanghai Municipality, China · Recruiting
Takeda Site 15
Paris, France · Recruiting
Takeda Site 17
Montpellier, Hérault, France · Withdrawn
Takeda Site 23
Bologna, Italy · Recruiting
Takeda Site 22
Rome, Lazio, Italy · Recruiting
Takeda Site 31
Verona, Veneto, Italy · Recruiting
Showing 40 of 52 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.